GlobeNewswire Inc.··NaAclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch
Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis